Genflow Biosciences to Attend BIO San Diego as Chairman Gad Berdugo Joins mRNA Panel

Genflow Biosciences plc (LON:GENF) will be present at BIO San Diego, which takes place from June 22 to June 25.

The London-listed biotechnology company, will attend the industry event in San Diego as part of its engagement with the wider life sciences and biotechnology community.

Genflow Bio chairman Gad Berdugo will also participate in an mRNA panel during the event. The panel is scheduled for Tuesday, June 23, from 7:30am to 9:00am Pacific Time, at Garibaldi, 901 Bayfront Ct Ste 1, San Diego, CA 92101.

The session is connected with the Alliance for mRNA Medicines, which brings together researchers and industry leaders working to advance mRNA research and support the development of new medicines for patients with serious diseases and unmet medical needs.

Genflow’s presence at BIO San Diego and Berdugo’s participation in the mRNA panel will place the company in discussions linked to biotechnology, therapeutic innovation and the development of new approaches in medicine.

Share on:

Written by: Jacob Brown

Find more news, interviews, share price & company profile here for:
Genflow Biosciences Plc

Latest Company News

Pet food industry turns to healthy ageing as demand for longevity products grows

October 19, 2026

Growing interest in pet longevity is creating opportunities for specialised nutrition, supplements and veterinary treatments. Improved research into the needs of ageing cats and dogs could help manufacturers develop products with clearer evidence of their health benefits.

Genflow Biosciences CEO Dr Eric Leire discusses SIRT6 gene therapy results in aged dogs

October 15, 2026

Genflow Biosciences CEO Dr Eric Leire discusses interim SLAB-VET trial results, the potential of SIRT6 gene therapy in ageing dogs, plasmid DNA delivery, veterinary licensing opportunities and progress across the company's human gene therapy programmes.

Genflow reports biological age reductions in dog gene therapy study

October 14, 2026

Genflow Biosciences reports reductions in measured epigenetic age in dogs receiving SIRT6c gene therapy, selecting intravenous plasmid DNA as its lead veterinary delivery method while further follow-up continues.

Genflow Biosciences secures Japanese patent and expands animal health partnerships

October 9, 2026

Genflow Biosciences has secured Japanese patent allowance for its SIRT6 gene therapy, with all 16 claims approved, and signed additional confidentiality agreements with animal health companies. Its regional grant application is under review, with no impact on financial guidance expected.

Genflow Biosciences: SLAB-VET Results Put SIRT6 Partnering and Human Therapies in Focus (video)

October 8, 2026

Genflow Biosciences’ latest SLAB-VET-001 results are sharpening the commercial case for its SIRT6c platform. CEO Dr Eric Leire discusses the signals seen in naturally aged dogs, why pDNA is leading the veterinary programme, growing interest from animal health companies and how progress could feed into Genflow’s human sarcopenia strategy.

Genflow Biosciences examines the role of genes in ageing

October 5, 2026

Genflow Biosciences is investigating a SIRT6 gene variant associated with longevity as part of its research into therapies targeting biological ageing.

Genflow Biosciences to Attend BIO San Diego as Chairman Gad Berdugo Joins mRNA Panel

Latest Company News

Search

Follow us on Social Media: